70083-21-5

Usage

Uses

Used in Pharmaceutical Research:
2-AMINO-N-(2-METHOXY-PHENYL)-BENZAMIDE is used as a research compound for exploring its potential in medicinal chemistry. Its unique structure and properties make it a valuable tool for studying the development of new drugs and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, 2-AMINO-N-(2-METHOXY-PHENYL)-BENZAMIDE is used as a chemical intermediate. It aids in the synthesis of more complex organic molecules, which can be further utilized in various applications, including pharmaceuticals and materials science.
Used in Drug Development:
2-AMINO-N-(2-METHOXY-PHENYL)-BENZAMIDE is employed as a candidate molecule in drug development. Its potential applications in treating various medical conditions are currently under investigation, with preclinical research indicating promising results.
Used in Medicinal Chemistry:
In medicinal chemistry, 2-AMINO-N-(2-METHOXY-PHENYL)-BENZAMIDE is used to study its pharmacological properties and explore its potential as a therapeutic agent. Understanding its interactions with biological targets can lead to the development of new drugs and treatment strategies.

InChI:InChI=1/C14H14N2O2/c1-18-13-9-5-4-8-12(13)16-14(17)10-6-2-3-7-11(10)15/h2-9H,15H2,1H3,(H,16,17)

Upstream product

• 118-48-9 isatoic anhydride 
• 90-04-0 2-methoxy-phenylamine 
• 21563-73-5 2-aminobenzoyl chloride 
• 118-92-3 anthranilic acid 
• 552-16-9 ortho-nitrobenzoic acid 
• 17296-34-3 N-(2-methoxyphenyl)-2-nitrobenzamide 

Downstream Products

• 133040-60-5 2-[2-(1H-Indol-3-yl)-ethyl]-3-(2-methoxy-phenyl)-3H-quinazolin-4-one 
• 3977-52-4 3-(2-methoxyphenyl)-4(3H)-quinazolinone 
• 1263153-06-5 ethyl 3-(o-methoxyphenyl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate 
• 1263153-05-4 C₁₈H₁₈N₂O₅ 
• 1379465-08-3 N-(2-methoxyphenyl)-2-(3-(4-nitrophenyl)ureido)benzamide 
• 712344-28-0 N-(2-methoxyphenyl)-2-(4-nitrobenzamido)benzamide 
• 1013275-87-0 N-(2-methoxyphenyl)-2-(4-nitrophenylsulfonamido)benzamide 
• 107559-07-9 3-(2-methoxyphenyl)benzo[d][1,2,3]triazin-4(3H)-one 
• 37856-18-1 3-(2-methoxyphenyl)-2-phenylquinazolin-4(3H)-one 
• 4260-28-0 2-methyl-3-(o-methoxyphenyl)-4(3H)-quinazolinone 
• 127662-29-7 3-(2-methoxy-phenyl)-1,2,3,4-tetrahydro-quinazoline 

Relevant academic research and scientific papers

Sustainable methine sources for the synthesis of heterocycles under metal- and peroxide-free conditions

Alcohols and ethers were identified as sustainable methine sources for synthesizing quinazolinone and benzimidazole derivatives using a combination of TsOH·H2O/O2 and appropriate bis-nucleophiles for the first time. Deuterium labeling studies clearly proved that the C2 hydrogen of the synthesized heterocycles came from the methine source. These unique reaction conditions were successfully applied to the synthesis of echinozolinone (2e′), 2f′ (a common precursor of rutaecarpine and (±) evodiamine), and dimedazole (6d). Notable features of this method include its low toxicity, use of commercial feedstocks as substrates, low cost, broad functional group tolerance and suitability for a wide range of bis-nucleophilic starting materials.

Sulfur-Promoted Synthesis of 2-Aroylquinazolin-4(3H)-ones by Oxidative Condensation of Anthranilamide and Acetophenones

A sulfur-promoted three-component reaction of isatoic anhydride, primary aliphatic or aromatic amines, and acetophenones leading to densely substituted 3-substituted 2-aroylquinazolin-4(3H)-ones is reported. The key step involves a cascade reaction of selective oxidation of the methyl group of the acetophenones, followed by a condensation with anthranilamides. The scope of the reaction is applicable to the synthesis of tryptanthrin and various 3-unsubstituted 2-aroylquinazolin-4(3H)-ones. (Figure presented.).

One-Pot, Multistep Reactions for the Modular Synthesis of N, N′-Diarylindazol-3-ones

The pot-economic synthesis of N,N′-diarylindazol-3-ones has been developed using readily available isatoic anhydrides, aryl amines, and aryl boronic acids. A Cu-catalyzed oxidative C-N cross-coupling and dehydrogenative N-N formation sequence under an air atmosphere affords indazol-3-one derivatives in good to excellent yields. Such process merges well with the preceding decarboxylative amination reaction, resulting in a more modular and straightforward approach.

Copper-catalyzed radical methylation/C-H amination/oxidation cascade for the synthesis of quinazolinones

A copper-catalyzed radical methylation/sp3 C-H amination/oxidation reaction for the facile synthesis of quinazolinone was developed. In this cascade reaction, dicumyl peroxide acts not only as a useful oxidant but also as an efficient methyl source. Notably, a methyl radical, generated from peroxide, was confirmed by electron paramagnetic resonance for the first time.

Discovery and characterization of 2-(cyclopropanesulfonamido)-n-(2-ethoxyphenyl)benzamide, ML382: A potent and selective positive allosteric modulator of MrgX1

Previous studies have shown that the activation of mouse MrgC11, a G-protein-coupled receptor, by its peptide ligand BAM8-22 can inhibit chronic pain. A large-scale screen has been carried out to isolate small-molecule allosteric agonists of MrgX1, the human homologue of MrgC11. The goal of this study is to improve the efficacy and potency of positive allosteric modulators (PAMs) with therapeutic implications in combating chronic pain. Herein we report an iterative parallel synthesis effort and a structure-activity relationship study of a series of arylsulfonamides which led to the discovery of the first PAM of MrgX1, ML382.

SAR and lead optimization of an HIV-1 Vif-APOBEC3G axis inhibitor

We describe structure-activity relationship and optimization studies of RN-18, an HIV-1 Vif-APOBEC3G axis inhibitor. Targeted modifications of RN-18 ring C, ring B, ring A, bridge A-B, and bridge B-C were performed to identify the crucial structural features, which generated new inhibitors with similar (4g and 4i) and improved (5, 8b, and 11) activities. Two potent water-soluble RN-18 analogues, 17 and 19, are also disclosed, and we describe the results of pharmacological studies with compound 19. The findings described here will be useful in the development of more potent Vif inhibitors and in the design of probes to identify the target protein of RN-18 and its analogues.

Synthesis, antimicrobial evaluation, ot-QSAR and mt-QSAR studies of 2-amino benzoic acid derivatives

A series of 2-amino benzoic acid derivatives (1-28) were synthesized and evaluated for their in vitro antimicrobial activity against the panel of Gram positive, Gram negative bacterial and fungal strains. The results of antimicrobial studies indicated that, in general, the synthesized compounds were found to be bacteriostatic and fungistatic in action. QSAR studies performed by the development of one target and multi target models indicated that multi-target model was effective in describing the antimicrobial activity as well demonstrated the effect of structural parameters viz. LUMO, 3χv and W on antimicrobial activity of 2-amino benzoic acid derivatives. Springer Science+Business Media, LLC 2010.

Synthesis of 3-aryl-2-[hydroxy(diaryl)methyl]-4-oxo-3,4-dihydroquinazolines

By heating arylamides of N-ethoxalylanthranilic acid in the acetic acid mediun in the presence of triethylamine the corresponding ethyl 3-aryl-4-oxo-3,4-dihydroquinazoline-2-carboxylates were obtained. The latter in the conditions of the Grignard reaction formed 3-aryl-2-[hydroxy-(diaryl)methyl] -4-oxo-3,4-dihydroquinazolines. Pleiades Publishing, Ltd., 2010.

Synthesis and in vitro study of platelet antiaggregant activity of 1,2,3,4-tetrahydroquinazoline derivatives

Some original 3-substituted 1,2,3,4-tetrahydroquinazolines were synthesized. Their antiplatelet activity was evaluated in vitro with respect to aggregation induced by the main inducers (ADP, collagen, arachidonic acid), platelet serotonin release reaction and thromboxane A2 synthesis. All these molecules possess an inhibiting power which, compared to that of aspirin in the same conditions, is the same or greater when aggregation is induced by ADP.